Eisai Corporation of North America announced today that the US Food and Drug Administration (FDA) has accepted for priority review a supplemental biologics license application (sBLA) for denileukin diftitox (Ontak). The sBLA seeks to convert an accelerated approval indication into full approval. It is based on a placebo-controlled phase III clinical trial to confirm the clinical effectiveness of the drug in certain patients with cutaneous T-cell lymphoma (CTCL).
Eisai Corporation of North America announced today that the US Food and Drug Administration (FDA) has accepted for priority review a supplemental biologics license application (sBLA) for denileukin diftitox (Ontak). The sBLA seeks to convert an accelerated approval indication into full approval. It is based on a placebo-controlled phase III clinical trial to confirm the clinical effectiveness of the drug in certain patients with cutaneous T-cell lymphoma (CTCL).
Denileukin diftitox is indicated for the treatment of patients with persistent or recurrent CTCL whose malignant cells express the CD25 component of the interleukin (IL)-2 receptor. The safety and efficacy of the agent in patients with CTCL whose malignant cells do not express the CD25 component of the IL-2 receptor have not been examined. Denileukin diftitox was granted accelerated approval under subpart E in February 1999.
Subpart E is an FDA regulation that allows the accelerated approval of a biologic agent based on a surrogate endpoint or an effect on a clinical endpoint other than survival and is most common in serious diseases or for medications that fill an unmet medical need. All subpart E approvals are contingent on the completion of postmarketing clinical trials that confirm a clinical benefit of the biologic agent.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
The Proper Ways to Identify and Use ADCs in Breast Cancer Subtypes
June 29th 2025Deciding when to use immunotherapy and how to utilize antibody-drug conjugates are complicated processes that require multidisciplinary collaboration to ensure that all patients with breast cancer receive appropriate and efficient care.
Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment
June 26th 2025Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.